Alumis (ALMS) Projected to Post Earnings on Wednesday

Alumis (NASDAQ:ALMS) is expected to be posting its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Alumis to post earnings of ($1.40) per share for the quarter.

Alumis Trading Up 1.4 %

NASDAQ:ALMS opened at $5.24 on Tuesday. The firm’s fifty day simple moving average is $7.11 and its 200 day simple moving average is $9.67. Alumis has a 1 year low of $4.74 and a 1 year high of $13.53.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Oppenheimer assumed coverage on shares of Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target on the stock. Robert W. Baird assumed coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price target on the stock. Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Finally, HC Wainwright decreased their price target on shares of Alumis from $26.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $26.57.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.